JCR Pharmaceuticals (4552) FY2026 FY Earnings Report

Quick View

Executive Summary

The Company returned to operating profitability from the operating loss recorded in the previous fiscal year, with both revenue growth and earnings improvement progressing concurrently. Revenue was ¥403.2B (+21.9% year on year), Operating Income was ¥5.5B (turning profitable from a loss of ¥62.2B in the previous year), Ordinary Income was ¥11.7B (versus a loss of ¥70.5B in the previous year), and Net Income was ¥22.1B (versus a loss of ¥44.0B in the previous year). The primary driver of earnings improvement was the emergence of operating leverage, supported by an improved gross margin accompanying revenue growth (74.9%, compared with 67.0% in the previous year) and restrained growth in SG&A expenses (+4.4%). However, Net Income included extraordinary income of ¥20.9B (including gains on the sale of investment securities) and foreign exchange gains of ¥7.1B; recurring earnings power therefore needs to be evaluated primarily based on Operating Income of ¥5.5B.

Factors Affecting Performance

【Revenue】Revenue increased 21.9% year on year to ¥403.2B. Although the Company operates as a single Pharmaceutical Business segment and does not disclose a business-by-business breakdown, gross profit expanded at a pace exceeding the ¥72.5B increase in revenue, rising by ¥80.7B year on year to ¥301.9B. This was accompanied by an improvement in the cost ratio, with cost of sales declining from ¥109.0B in the previous year to ¥101.3B.

【Profit and Loss】Operating Income turned profitable at ¥5.5B, compared with a loss of ¥62.2B in the previous fiscal year. SG&A expenses increased only +4.4% to ¥296.3B, compared with revenue growth of 21.9%, causing the SG&A ratio to decline from 85.8% to 73.5% and operating leverage to become evident. Ordinary Income of ¥11.7B benefited from foreign exchange gains of ¥7.1B, while extraordinary income of ¥20.9B, primarily gains on the sale of investment securities, was added to Profit Before Tax of ¥32.2B, resulting in Net Income of ¥22.1B. The growth in Ordinary Income and Net Income was highly dependent on extraordinary income and foreign exchange gains. Although the Company achieved both revenue and earnings growth, it should be noted that the quality of earnings improvement includes temporary factors.

Segment Analysis

The Group operates as a single Pharmaceutical Business segment and does not disclose segment-specific information.

Key Financial Indicators

【Profitability】The Operating Income margin improved substantially to 1.4% from -18.8% in the previous year, although the absolute level remains low. The Net Income margin was 5.4%, substantially exceeding the Operating Income margin, indicating dependence on extraordinary income and foreign exchange gains. ROE was 4.6%, while ROA remained at approximately 2.0%.【Cash Flow Quality】Operating Cash Flow (OCF) was a negative ¥1.4B. The OCF-to-Net Income ratio was negative relative to Net Income of ¥22.1B, indicating that earnings have not yet been converted into cash. Increases of ¥19.3B in accounts receivable and ¥18.5B in inventories placed pressure on working capital.【Investment Efficiency】Capital expenditures were ¥114.3B, approximately 4.5 times depreciation and amortization expense of ¥25.6B. Construction in progress accumulated to ¥194.1B, approximately 49% of property, plant and equipment. Monetization of the investments remains limited at this stage relative to their scale.【Financial Soundness】The Equity Ratio declined slightly to 43.4% from 45.1% in the previous year. Short-term borrowings increased +65.6% to ¥380.9B, accounting for 75.7% of current liabilities. Cash and deposits of ¥140.1B were below short-term borrowings, indicating increased dependence on interest-bearing debt.

Cash Flow Analysis

Operating Cash Flow was a negative ¥1.4B, representing a substantial improvement from the negative ¥54.9B recorded in the previous year, but remained negative. OCF was negative despite Net Income of ¥22.1B because increases of ¥19.3B in accounts receivable and ¥18.5B in inventories accompanying revenue growth placed pressure on cash. Investing Cash Flow was a negative ¥125.0B, primarily due to capital expenditures of ¥114.3B, and the Company continued to make aggressive investments substantially exceeding depreciation and amortization expense of ¥25.6B. Free Cash Flow, calculated as the sum of OCF and Investing Cash Flow, was a substantial negative ¥126.4B. Financing Cash Flow was positive ¥133.1B, with the net increase in short-term borrowings (+¥150.9B) funding this cash requirement. The Company is relying on short-term debt to fund investment and working capital requirements; improvement in OCF after the facilities become operational will be a key focus for future liquidity management.

Quality of Earnings

The improvement in earnings comprised both a recovery in operating leverage in the core business and temporary factors. Operating Income of ¥5.5B reflects core business improvement resulting from revenue growth and restrained SG&A expense growth. However, Ordinary Income of ¥11.7B benefited from foreign exchange gains of ¥7.1B as non-operating income, while extraordinary income of ¥20.9B, including gains on the sale of investment securities and other items, was added to Profit Before Tax of ¥32.2B. Of Net Income of ¥22.1B, the increase over Ordinary Income amounted to ¥10.1B, with extraordinary income accounting for most of the increase. Accordingly, the Net Income margin of 5.4% substantially exceeded the Operating Income margin of 1.4%, and recurring earnings power should be assessed on an Operating Income basis. In addition, the fact that OCF was negative ¥1.4B indicates that reported earnings were not supported by cash generation. From an accrual perspective—the divergence between accounting earnings and cash flow—the quality of earnings therefore warrants attention.

Earnings Forecast and Guidance

Progress against the full-year Company forecasts was 88.2% for revenue against a forecast of ¥457.0B and 50.5% for Operating Income against a forecast of ¥11.0B. Meanwhile, Ordinary Income had already reached ¥11.7B, or 233.0% progress against the Company forecast of ¥5.0B, while EPS of ¥17.87 as of the first half substantially exceeded the forecast EPS of ¥1.64. This high progress for Ordinary Income and Net Income reflects dependence on extraordinary income, including foreign exchange gains and gains on the sale of securities. From the second half onward, the extent to which the Operating Income forecast is achieved will be the substantive focus of performance evaluation.

Shareholder Returns

The annual dividend was ¥20 per share, increased from ¥10 in the previous year, resulting in total dividends of approximately ¥24.4B. The Payout Ratio was 119.1% relative to Net Income of ¥22.1B, indicating that dividends could not be funded solely from current-period earnings. Given Free Cash Flow of negative ¥126.4B, the dividend for the current period was supported not by operating or investing cash flow but by retained earnings of ¥312.3B and financing. A comprehensive assessment of dividend sustainability, including the status of OCF improvement, is therefore required.

Risk Factors

1. Risk of prolonged working capital cycle: OCF was negative due to increases of ¥19.3B in accounts receivable and ¥18.5B in inventories. The Company has a structure in which revenue growth directly leads to increased funding requirements, making collection and inventory management efficiency key to future cash flow improvement.

2. Refinancing risk due to dependence on short-term debt: Short-term borrowings increased +65.6% year on year to ¥380.9B, accounting for 75.7% of current liabilities. Cash and deposits of ¥140.1B were below short-term borrowings, resulting in high sensitivity to refinancing terms and interest rate trends.

3. Operationalization and recovery risk associated with large-scale investments: Construction in progress has accumulated to ¥194.1B, approximately 49% of property, plant and equipment. Capital expenditures of ¥114.3B reached approximately 4.5 times depreciation and amortization expense. The conversion of these investments into revenue and cash flow after commencement of operations will be a key inflection point for improving capital efficiency.

Industry Benchmark (For Reference; Company Analysis)

Industry Benchmark (pharma)

Profitability and Returns

The Company’s Operating Income margin and Net Income margin substantially exceed the industry median, indicating relatively favorable profitability within the industry.

Growth and Capital Efficiency

The Company’s revenue growth rate also substantially exceeds the industry median, demonstrating a high pace of revenue growth within the industry.

※Source: Company analysis

Key Takeaways from the Financial Results

1. The Operating Income margin improved from -18.8% in the previous fiscal year to 1.4%. The emergence of operating leverage through an improved gross margin (74.9%) and lower SG&A ratio (73.5%) indicates structural improvement in the core business.

2. Of Net Income of ¥22.1B, the ¥10.1B increase over Ordinary Income was primarily attributable to extraordinary income of ¥20.9B, while foreign exchange gains of ¥7.1B also contributed to higher Ordinary Income. When assessing recurring earnings power, it is useful to confirm performance on an Operating Income basis excluding these temporary factors.

3. The combination of negative OCF of ¥1.4B, negative Free Cash Flow of ¥126.4B, and a +65.6% increase in short-term borrowings indicates a change in the funding structure during a period of revenue growth and investment. The progress of capital expenditure commissioning and improvement in working capital efficiency will influence future liquidity trends.

Theoretical Share Price (Reference Value)

Sensitivity: ¥284–¥299 at ±1% for the cost of equity, and ¥289–¥293 at ±0.1 for ω.

Notes:

• Net Income is substantially compressed relative to Operating Income due to tax burden, acquisition-related expenses, non-controlling interests, and other factors (Net Income ÷ Operating Income 18%). This value reflects that compression at face value; if the factors are temporary, underlying earnings power may be higher than this figure.
• Because forecast ROE is below the cost of equity, the theoretical value is below book value per share.

(Calculation model: Residual Income Model (Ohlson-type; explicit 5-year fade) / Interest rate reference month: 2026-07 / Mechanically calculated solely from publicly disclosed data; this is not a forecast of the market share price or a recommendation of any specific investment action, and does not predict or guarantee future share prices.)

---

This report is an automatically generated earnings analysis document produced by AI analysis of XBRL earnings summary data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own discretion and responsibility, with consultation with a professional advisor as necessary.

---End of Report---